Rani Therapeutics Holdings (RANI) Equity Average (2021 - 2026)
Rani Therapeutics Holdings' Equity Average history spans 6 years, with the latest figure at $38.5 million for Q1 2026.
- On a quarterly basis, Equity Average rose 4251.67% to $38.5 million in Q1 2026 year-over-year; TTM through Mar 2026 was $38.5 million, a 4251.67% increase, with the full-year FY2025 number at $22.5 million, up 55.53% from a year prior.
- Equity Average came in at $38.5 million for Q1 2026, up from $16.8 million in the prior quarter.
- The five-year high for Equity Average was $116.1 million in Q1 2022, with the low at -$8.5 million in Q3 2025.
- Historically, Equity Average has averaged $39.2 million across 5 years, with a median of $30.1 million in 2023.
- Biggest five-year swings in Equity Average: crashed 250.23% in 2025 and later soared 4251.67% in 2026.
- Year by year, Equity Average stood at $80.3 million in 2022, then crashed by 62.48% to $30.1 million in 2023, then tumbled by 84.62% to $4.6 million in 2024, then soared by 263.1% to $16.8 million in 2025, then soared by 128.98% to $38.5 million in 2026.
- Business Quant data shows Equity Average for RANI at $38.5 million in Q1 2026, $16.8 million in Q4 2025, and -$8.5 million in Q3 2025.